The objectives of the contract are to advance the development of Soligenix's thermostabilization technology, ThermoVax, combined with the company's ricin toxin vaccine, Rivax, as a medical countermeasure (MCM) to prevent the effects of ricin exposure.
A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been...
Elanco, the animal health division of Eli Lilly and Company, and Dow AgroSciences LLC, a wholly...
Merck and Sun Pharmaceutical Industries have announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis.
The board of Auxilium Pharmaceuticals has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker.
EMD Serono and Sutro Biopharma announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.
Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.
Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.
MedGenesis Therapeutix has entered into an agreement with Pfizer, granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.
AstraZeneca and Eli Lilly announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.
Allergan and Pershing Square are agreeing on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold special shareholders meeting, as Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker.
New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from discontinuing its drug widely used to treat Alzheimer's patients, arguing the company is illegally driving patients to its newer patented drug to avoid losses from cheaper generic alternatives coming out next year.
Shares of Avanir Pharmaceuticals soared Monday after the company reported positive clinical trial results for a drug that is designed to treat agitation in Alzheimer's disease patients. The company said patients who were treated with AVP-923 were less agitated than patients given a placebo.
Vernalis and Tris Pharma announced that the FDA has confirmed that the New Drug Application for Tuzistra XR has been accepted for full review. This triggers a milestone payment from Vernalis to Tris.
Gilead Sciences says it has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries.
The Livestrong cancer charity is reporting a sharp drop in donations and revenue after founder Lance Armstrong admitted taking performance-enhancing drugs during most of his record-setting cycling career.
Abbott Laboratories said Thursday that its board approved spending up to $3 billion to buy back the health conglomerate's stock.
The award will support the continued advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of hematopoietic sub-syndrome of Acute Radiation Syndrome (ARS).
Baxter International has announced that Baxalta Incorporated will be the name of the new, publicly traded biopharmaceutical company that is expected to launch in mid-2015.
The Seattle-based foundation said the money will go to the United Nations, the World Health Organization, the U.S. Centers for Disease Control and Prevention and international organizations involved in fighting transmission of the virus.
PharmAthene Awarded Contract Of Up To $28.1M to Develop Next Generation Thermostable Anthrax VaccineSeptember 10, 2014 9:12 am | News | Comments
PharmAthene announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded the company a contract, valued at up to $28.1M if all contract options are exercised, for the development of a next generation anthrax vaccine based on the company's proprietary rPA anthrax vaccine technology platform.
Under the new agreement, Genmab will pay an upfront fee of $11M for exclusive rights to utilize Seattle Genetics' auristatin-based ADC technology with Genmab'sHuMax(R)-AXL, an antibody targeting AXL which is expressed on multiple types of solid cancers.
Auxilium Pharmaceuticals said Tuesday it is cutting 30 percent of its workforce, about 190 jobs, as part of a restructuring of its operations that will save it at least $75 million a year.
China's premier promised Wednesday to open the world's No. 2 economy wider to foreign companies, promising favorable conditions despite a wave of anti-monopoly investigations that business groups say might be aimed at limiting competition.
Mylan has entered into an agreement to acquire the U.S. commercialization, marketing and intellectual property rights relating to Arixtra® (fondaparinux sodium) Injection and the authorized generic (AG) of Arixtra from Aspen Global Incorporated.
A former portfolio manager convicted of helping his firm earn more than a quarter-billion dollars illegally through insider trading on a promising Alzheimer's drug trial was sentenced Monday to nine years in prison by a judge who said lengthy incarceration was earned with a staggering fraud that was the biggest of its kind.
Merus Labs International has acquired from Novartis AG, in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom® (acenocoumarol).
Ophthotech Achieves $50M Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista®September 8, 2014 8:07 am | News | Comments
Ophthotech Corporation today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD).
- Page 1